Today announced the presentation of interim outcomes from the first Phase I/II trial of samalizumab.

Alexion Pharmaceuticals reports interim results from stage 1 trial on samalizumab antibody Alexion Pharmaceuticals, Inc. today announced the presentation of interim outcomes from the first Phase I/II trial of samalizumab, the company’s investigational, first-in-course humanized monoclonal antibody. The ongoing trial is analyzing the basic safety, maximum tolerated dosage, pharmacokinetics, and pharmacodynamics of samalizumab in adult individuals with advanced stage B-cell persistent lymphocytic leukemia or multiple myeloma . Data offered today at the 52nd American Society of Hematology Annual Achieving and Exposition in Orlando indicate that samalizumab was well tolerated at all dosages studied, exhibited a dose-dependent biological and pharmacokinetic response, and exhibited initial evidence of anti-tumor activity.All vaccines were far more efficacious in abating the U.S. Strain. The researchers state identification of the properties of the African viruses would open the entranceway to developing a more potent vaccine against contamination now rampant in sub-Saharan Africa. This is important, they state, because genital herpes patients are more vulnerable to HIV/AIDS infection, as the open up sores symptomatic of herpes include a high concentration of immune cells that are targeted by HIV. The challenge lies in formulating either a one vaccine that protects against both types of strains of the genital herpes virus or two different vaccines.